Oral Presentations
Objectives: Evaluate whether the presence of preoperative thyroglobulin antibody (TgAb) levels can help predict the final pathology of thyroid nodules. Assess whether higher levels of preoperative TgAb increase the likelihood that a thyroid nodule is malignant.
Methods: A retrospective chart review of patients who underwent thyroidectomy in 3 McGill University-affiliated hospitals between January 2012 and 2014 was conducted. Demographic data, TgAb levels, and final histopathology were recorded. Patients were divided into 2 groups: TgAb positive (defined as TgAb ≥30 IU/mL) and TgAb low/ negative (defined as TgAb <30). Micropapillary thyroid carcinomas were considered to be benign. These data were then statistically analyzed using SPSS.
Results: Preoperative TgAb levels were available in 412 patients. There were 360 patients in the TgAb low/negative group (malignancy rate: 51.39%) and 52 patients in the TgAb positive group (malignancy rate: 65.38%). The sensitivity, specificity, positive predictive value, and negative predictive value of TgAb ≥30 IU/mL as a diagnostic test for thyroid malignancy were 15.53% (confidence interval [CI] 11.00-21.01), 90.67% (CI 85.66-94.38), 65.38% (50.91-78.03), and 48.61% (CI 43.34-53.91), respectively. The relative risk was 1.2723 (CI 1.0192-1.5883) and the odds ratio was 1.7868 (CI 0.9732-3.2804 ). Both the Pearson chi-square test (P = .024) and Fisher's exact test (P = .017) yielded statistical significance between the 2 groups.
Conclusions: Our study demonstrates that patients with preoperative TgAb ≥30 IU/mL had a higher rate of malignancy when compared to patients with TgAb <30 IU/mL. This suggests that an elevated TgAb level may increase the risk that a thyroid nodule is malignant.
Cervical Lymph Node P16 Status in Diagnosis of the unknown Primary
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Objectives: (1) Evaluate the role of p16 status of cervical lymph node (LN) metastases in localizing carcinoma of unknown primary (CUP). (2) Compare the sensitivity, specificity, and accuracy of positron emission tomography PET scan for locating the primary site in the setting of p16 positive and p16 negative LN metastases.
Methods: Retrospective review of 30 patients that were identified from archived tumor board lists from 2010 to 2013. All patients presented to a tertiary care center with squamous cell carcinoma metastases to cervical LN of unknown source despite initial clinical evaluation and computed tomography scan. Fine needle biopsy or excisional biopsy specimens were tested for the p16 biomarker. The accuracy of the PET scan was assessed by comparing the fludeoxyglucose-avid predicted site against a standard panendoscopy with directed biopsies.
Results: A primary was identified in 61% of cases presenting as CUP. All p16+ LN metastases were from an oropharyngeal primary or remained unknown. All primaries located outside the upper aerodigestive tract were p16-. The sensitivity and specificity of PET in patients with p16+ LN metastases were worse than in p16-metastases (71%, 33% vs 100%, 100%).
Conclusions: LN p16 status can help localize CUP. In our series, the sensitivity and specificity of PET scan were much worse in p16+ LN metastases. PET scan may be of limited utility for localizing CUP with p16+ LN metastasis.
